These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37842948)

  • 1. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview.
    Song YJ; Nam SW; Suh CH; Choe JY; Yoo DH
    Expert Opin Drug Metab Toxicol; 2023; 19(11):751-768. PubMed ID: 37842948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT-P13 in the treatment of rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT-P13 SC for the treatment of rheumatoid arthritis.
    Westhovens R
    Expert Rev Clin Immunol; 2022 Jan; 18(1):5-13. PubMed ID: 34842032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
    Yoo DH; Oh C; Hong S; Park W
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
    Caporali R; Allanore Y; Alten R; Combe B; Durez P; Iannone F; Nurmohamed MT; Lee SJ; Kwon TS; Choi JS; Park G; Yoo DH
    Expert Rev Clin Immunol; 2021 Jan; 17(1):85-99. PubMed ID: 33305638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU.
    Shirley M
    Clin Drug Investig; 2021 Dec; 41(12):1099-1107. PubMed ID: 34727347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.
    Alten R; An Y; Kim DH; Yoon S; Peyrin-Biroulet L
    Clin Drug Investig; 2022 Jun; 42(6):477-489. PubMed ID: 35657560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of infliximab and its biosimilars in patients with rheumatoid arthritis presenting an insufficient response to methotrexate : A network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2023 Mar; 82(2):114-122. PubMed ID: 34228181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
    Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
    Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
    Yoo DH; Racewicz A; Brzezicki J; Yatsyshyn R; Arteaga ET; Baranauskaite A; Abud-Mendoza C; Navarra S; Kadinov V; Sariego IG; Hong SS; Lee SY; Park W
    Arthritis Res Ther; 2016 Apr; 18():82. PubMed ID: 27038608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?
    Lee H
    AAPS J; 2014 Jan; 16(1):22-6. PubMed ID: 24114449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.
    Kawashiri SY; Shimizu T; Sato S; Morimoto S; Kawazoe Y; Sumiyoshi R; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Jul; 99(30):e21151. PubMed ID: 32791688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis.
    Hanrahan C; Lee T
    Am J Health Syst Pharm; 2021 Mar; 78(8):697-704. PubMed ID: 33599738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.
    Takeuchi T; Yamanaka H; Tanaka Y; Sakurai T; Saito K; Ohtsubo H; Lee SJ; Nambu Y
    Mod Rheumatol; 2015; 25(6):817-24. PubMed ID: 25736355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
    Blair HA; Deeks ED
    BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.